Similar articles

• The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

  Lévesque LE, Brophy JM, Zhang B. Lévesque LE, et al. Ann Intern Med. 2005 Apr 5;142(7):481-9. doi: 10.7326/0003-4819-142-7-200504050-00113. Ann Intern Med. 2005. PMID: 15809459
• The risk for myocardial infarction with cyclooxygenase-2 inhibitors.

  Shinmura K, Bolli R. Shinmura K, et al. Ann Intern Med. 2005 Oct 18;143(8):617; author reply 617-8. doi: 10.7326/0003-4819-143-8-200510180-00022. Ann Intern Med. 2005. PMID: 16230737 No abstract available.
• The risk for myocardial infarction with cyclooxygenase-2 inhibitors.

  Pijak MR, Huzicka I, Gazdik F. Pijak MR, et al. Ann Intern Med. 2005 Oct 18;143(8):616-7; author reply 617-8. doi: 10.7326/0003-4819-143-8-200510180-00021. Ann Intern Med. 2005. PMID: 16230736 No abstract available.
• Cox-2 inhibitors and cardiovascular risk: the data are inconclusive, and these drugs are needed.

  Lipani J. Lipani J. Cleve Clin J Med. 2001 Nov;68(11):961-2. doi: 10.3949/ccjm.68.11.961. Cleve Clin J Med. 2001. PMID: 11718437 Review. No abstract available.
• The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.

  Konstantinopoulos PA, Lehmann DF. Konstantinopoulos PA, et al. J Clin Pharmacol. 2005 Jul;45(7):742-50. doi: 10.1177/0091270005278202. J Clin Pharmacol. 2005. PMID: 15951464 Review.